Move to topTop
March 28, 2017

Leuven (Belgium), March 28, 2017 - Terumo Europe N.V. today announced the first commercial clinical case using QuiremSpheres® - the next generation radioembolization microspheres for advanced unresectable liver cancer.

QuiremSpheres®, the next generation of radio-embolization microspheres, are the only commercially available microspheres that contain the radioactive isotope Holmium-166. In recent trials, holmium microspheres were shown to be safe[1] and effective[2] for the treatment of advanced liver cancer.

Unlike the widely adopted Yttrium-90 microspheres, QuiremSpheres® can be visualized in low concentrations by means of SPECT and MRI. This allows clinicians to quantitatively assess the distribution of microspheres in the liver, enabling accurate evaluation of treatment directly after the radio-embolization procedure.

QuiremSpheres® have been used for the first time outside of a research setting, in clinical practice at the University Clinic Carl Gustav Carus in Dresden, Germany. A multidisciplinary team, consisting of Prof. Dr. med R.T.Hoffmann and Prof. Dr. med. J. Kotzerke and their dedicated teams performed the radioembolization procedure on a patient with metastatic colorectal cancer in the liver.

Prof. Dr. med. R. Hoffmann, Head of Interventional Radiology at the University Clinic Carl Gustav Carus said "As a radiologist, I value the unique imaging capabilities of QuiremSpheres®. SPECT and MR-imaging opens new opportunities that we look forward to exploring. This will give us the confidence we need to start individualizing treatments."

In addition to the unique imaging capabilities, Holmium-166 also has a shorter half-life than Yttrium-90 [3]. Prof. Dr. med. J. Kotzerke, Head of the Nuclear Medicine department at the University Clinic Carl Gustav Carus commented: "The short halftime of holmium-166 results in a high initial dose rate. Therefore, we expect to see an improved radiobiological effect."

In reflection of the physician-led collaboration for the development of this treatment, Prof. Dr. M. Lam, heading the Nuclear Medicine department of the University Medical Center Utrecht in the Netherlands said "I am excited to see this treatment, which has been developed at our hospital, now becomes available for patients across Europe."

Peter Coenen, President of Interventional systems Terumo EMEA said: "We are grateful for the confidence that the Dresden clinical team places in us and QuiremSpheres®. We strongly believe that the unique imaging capabilities of QuiremSpheres® can be a game changer in the field of radio-embolization and this first patient treatment is an important milestone towards realizing its full potential."

Jan Sigger, CEO of Quirem Medical B.V. - the manufacturer of QuiremSpheres® said: "We are excited that, after more than 15 years of research, QuiremSpheres® has become available for clinical use. Through our strategic partnership with Terumo, liver cancer patients across Europe can now benefit from the next generation microspheres for radio-embolization."

  • [1]

    The recommended whole liver dose of 60Gy was identified as the maximum tolerated radiation dose in a phase I trial (no dose-limiting toxicity occured in the 60Gy cohort) Smits et al, Lancet Oncol. 2012, Oct;13(10):1025-34. ClinicalTrials.gov Identifier: NCT01031784

  • [2]

    Study results have been published in PhD thesis of J.F. Prince; ISBN 978-90-393-6489-5; 2016. Publication in peer-reviewed journal is expected soon. ClinicalTrials.gov Identifier: NCT01612325

  • [3]

    Nijsen et al. European Journal of Nuclear Medicine, 1999, Jul; 26(7): 699-704

About Quirem

Quirem Medical is an emerging medical device company with a mission to develop the next generation microspheres for targeted interventional treatment of liver malignancies. It is based in Deventer, the Netherlands and is a spin-off company from the University Medical Center in Utrecht.

About Terumo

Terumo (TSE: 4543) is a global leader in medical technology and has been committed to “Contributing to Society through Healthcare” for 100 years. Based in Tokyo and operating globally, Terumo employs more than 28,000 associates worldwide to provide innovative medical solutions in more than 160 countries and regions. The company started as a Japanese thermometer manufacturer, and has been supporting healthcare ever since. Now, its extensive business portfolio ranges from vascular intervention and cardio-surgical solutions, blood transfusion and cell therapy technology, to medical products essential for daily clinical practice such as transfusion systems, diabetes care, and peritoneal dialysis treatments. Terumo will further strive to be of value to patients, medical professionals, and society at large.

Among the information that Terumo discloses, the forward-looking statements including financial projections are based upon our assumptions using information available to us at the time and are not intended to be guarantees of future events or performance. Accordingly, it should be noted that actual results may differ from those forecasts or projections due to various factors. Factors affecting to actual results include, but are not limited to, changes in economic conditions surrounding Terumo, fluctuations of foreign exchange rates, and state of competition.

 

Information about products (including products currently in development) included in this material is not intended to constitute an advertisement or medical advice.